Registration and Fees

PLEASE NOTE: This year’s Bone School will operate an application system for delegates.  When you have been notified that you have a place at the School you will be able to complete your registration and pay for your place along with your accommodation.  The registration form will open after 30 November 2024. 

Fee includes:

  • Lunch and tea/coffee breaks on all 3 days of course
  • Attendance at all sessions and workshops
  • Tuesday evening Welcome dinner
  • Group dinners on Wednesday 28 and Thursday 29 May 
  • Printed school programme book
  • Access to all course materials on line

To download the Eligibility Form for the discounted rate please click here

If cancelled on or before 28 February 2024 – 100% of the registration fee is refundable.

If cancelled from 1 March to 31 March 2024 – 70% of the registration fee is refundable.

No refunds are payable from 1 April 2024 onwards

Registration Form

(this will open on 30 November 2024 for those who have been notified that they have been allocated a place at the school)

To register in-person:

To register on behalf of someone else:

Social Programme

Tuesday 27 May          

Delegates can join us for our Welcome buffet dinner depending on when they arrive or of course they may wish to visit nearby Annecy and have dinner there at their leisure.

Wednesday 28 May 
Group dinner at Les Pensieres included in the registration fee.

Thursday 29 May 
We will have a Group dinner at an nearby venue.  We will travel together into Annecy town for dinner.  This is also included in the registration fee.

Course refreshments

All coffee breaks and lunches as detailed in the programme during the three day course will be included in your registration fee.  The menus and style of lunches will change each day, but we have programmed an hour for lunch breaks on Wednesday and Thursday and on the final day we will run a buffet so that the lunch is flexible for delegates to have some food before their onward journey.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.